Literature DB >> 24966332

Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland.

Ilkka Paatero1, Tiffany N Seagroves2, Katri Vaparanta3, Wen Han4, Frank E Jones4, Randall S Johnson5, Klaus Elenius6.   

Abstract

Conditional knock-out of Hif1a in the mouse mammary gland impairs lobuloalveolar differentiation during lactation. Here, we demonstrate that expression of ErbB4 was reduced in the lobulalveoli of mice with mammary gland-specific deletion of Hif1a. Erbb4 was not, however, a direct target gene for transcriptional regulation by HIF-1α in vitro. HIF-1α overexpression or HIF accumulating prolyl hydroxylase inhibitors reduced ErbB4 endocytosis, promoted transcriptional co-regulatory activity of ErbB4, and stimulated ErbB4-induced differentiation of mammary carcinoma cells. Consistently, RNA interference-mediated down-regulation of HIF-1α resulted in reduced ErbB4 protein amount and reduced mammary carcinoma cell differentiation. These findings indicate that HIF-1α is a physiologically relevant regulator of ErbB4 and that ErbB4 is involved in HIF-regulated differentiation of the mammary gland.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cell Signaling; Epidermal Growth Factor Receptor (EGFR); ErbB4; Growth Factor; Hypoxia-inducible Factor (HIF); Lactation; Mammary Gland; Receptor Tyrosine Kinase; Signal Transduction

Mesh:

Substances:

Year:  2014        PMID: 24966332      PMCID: PMC4139252          DOI: 10.1074/jbc.M113.533497

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Hypoxia signalling in cancer and approaches to enforce tumour regression.

Authors:  Jacques Pouysségur; Frédéric Dayan; Nathalie M Mazure
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Mitogen-activated protein kinase kinase inhibition decreases growth hormone stimulated transcription mediated by STAT5.

Authors:  T J Pircher; A Flores-Morales; A L Mui; A R Saltiel; G Norstedt; J A Gustafsson; L A Haldosén
Journal:  Mol Cell Endocrinol       Date:  1997-10-20       Impact factor: 4.102

3.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.

Authors:  Jorma A Määttä; Maria Sundvall; Teemu T Junttila; Liisa Peri; V Jukka O Laine; Jorma Isola; Mikala Egeblad; Klaus Elenius
Journal:  Mol Biol Cell       Date:  2005-10-26       Impact factor: 4.138

4.  Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility.

Authors:  Tien Hsu; Yair Adereth; Nurgun Kose; Vincent Dammai
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

5.  Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.

Authors:  Hernán García-Rivello; Julián Taranda; Matilde Said; Patricia Cabeza-Meckert; Martin Vila-Petroff; Jorge Scaglione; Sergio Ghio; Ju Chen; Cary Lai; Ruben P Laguens; Kent C Lloyd; Cecilia M Hertig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-04-29       Impact factor: 4.733

6.  Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

Authors:  Teemu T Junttila; Maria Sundvall; Mikael Lundin; Johan Lundin; Minna Tanner; Pirkko Härkönen; Heikki Joensuu; Jorma Isola; Klaus Elenius
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

7.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.

Authors:  M Gassmann; F Casagranda; D Orioli; H Simon; C Lai; R Klein; G Lemke
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

8.  Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development.

Authors:  N C Luetteke; T H Qiu; S E Fenton; K L Troyer; R F Riedel; A Chang; D C Lee
Journal:  Development       Date:  1999-06       Impact factor: 6.868

9.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Authors:  Christopher C Williams; June G Allison; Gregory A Vidal; Matthew E Burow; Barbara S Beckman; Luis Marrero; Frank E Jones
Journal:  J Cell Biol       Date:  2004-11-08       Impact factor: 10.539

10.  ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation.

Authors:  F E Jones; T Welte; X Y Fu; D F Stern
Journal:  J Cell Biol       Date:  1999-10-04       Impact factor: 10.539

View more
  5 in total

1.  ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.

Authors:  J O Humtsoe; E Pham; R J Louie; D A Chan; R H Kramer
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

2.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.

Authors:  Christopher S Williams; Jessica K Bernard; Michelle Demory Beckler; Dana Almohazey; Mary Kay Washington; Jesse J Smith; Mark R Frey
Journal:  Carcinogenesis       Date:  2015-04-27       Impact factor: 4.944

3.  Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Authors:  Astrid A Glück; Eleonora Orlando; Dominic Leiser; Michaela Poliaková; Lluís Nisa; Aurélie Quintin; Jacopo Gavini; Deborah M Stroka; Sabina Berezowska; Lukas Bubendorf; Andree Blaukat; Daniel M Aebersold; Michaela Medová; Yitzhak Zimmer
Journal:  Oncogene       Date:  2018-05-02       Impact factor: 9.867

4.  Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors.

Authors:  Ibrahim H Kankia; Poornima Paramasivan; Matthew Elcombe; Simon P Langdon; Yusuf Y Deeni
Journal:  Explor Target Antitumor Ther       Date:  2021-04-30

Review 5.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.